BioCentury
ARTICLE | Clinical News

Alagebrium: Phase IIa halted

June 13, 2005 7:00 AM UTC

ALT said FDA placed a clinical hold on enrollment in its Phase IIa EMERALD trial of alagebrium in ED due to preclinical toxicity studies showing liver alterations in rats. ALT voluntarily halted this ...